Related references
Note: Only part of the references are listed.Radiosynthesis of N-[11C]-methyl-hydroxyfasudil as a new potential PET radiotracer for rho-kinases (ROCKs)
Ana C. Valdivia et al.
APPLIED RADIATION AND ISOTOPES (2010)
Applications for ROCK kinase inhibiton
Michael F. Olson
CURRENT OPINION IN CELL BIOLOGY (2008)
Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons
Kentaro Yamashita et al.
BRAIN RESEARCH (2007)
Development of Rho-kinase inhibitors for cardiovascular medicine
Hiroaki Shimokawa et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
A feasibility study of [11C]SA4503-PET for evaluating sigma1 receptor occupancy by neuroleptics:: the binding of haloperidol to sigma1 and dopamine D2-like receptors
Kiichi Ishiwata et al.
ANNALS OF NUCLEAR MEDICINE (2006)
Molecular mechanisms and therapeutic strategies of chronic renal injury: Renoprotective effect of Rho-kinase inhibitor in hypertensive glomerulosclerosis
T Nishikimi et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2006)
Efficacy and safety of fasudil in patients with stable angina - A double-blind, placebo-controlled, phase 2 trial
RM Vicari et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Effects of fasudil in acute ischemic stroke: Results of a prospective placebo-controlled double-blind trial
M Shibuya et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2005)
Inhibition of rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection
Y Rikitake et al.
STROKE (2005)
Rho kinase, a promising drug target for neurological disorders
BK Mueller et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration
D Lepley et al.
CANCER RESEARCH (2005)
Beneficial effect of hydroxyfasudil, a specific Rho-kinase inhibitor, on ischemia/reperfusion injury in canine coronary microcirculation in vivo
T Yada et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
ROCKs as therapeutic targets in cardiovascular diseases
Yoshiyuki Rikitake et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2005)
Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK
S Pedrini et al.
PLOS MEDICINE (2005)
Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C
S Sanada et al.
CIRCULATION (2004)
Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Aβ42 by inhibiting Rho
Y Zhou et al.
SCIENCE (2003)
Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system
CI Dubreuil et al.
JOURNAL OF CELL BIOLOGY (2003)
A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction
S Cellek et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2002)
The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway
Y Sasaki et al.
PHARMACOLOGY & THERAPEUTICS (2002)
Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases
H Shimokawa
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2002)
Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage
S Satoh et al.
LIFE SCIENCES (2001)
A new model of cerebral microthrombosis in rats and the neuroprotective effect of a rho-kinase inhibitor
Y Toshima et al.
STROKE (2000)